Hikma is a high-barrier pharmaceutical leader trading at a distressed valuation after a temporary injectables margin reset, with buybacks, Bedford capacity, biosimilars, inhalation products, and MENA growth offering a credible path to re-rating.
Overview
Hikma Pharmaceuticals is a diversified multinational generics and specialty pharma group with strong positions in US injectables, MENA branded medicines, and North American generics/CMO services. FY2025 core revenue reached $3.35 billion, led by Injectables at 42.5% of sales, Hikma Rx at 31.0%, and Branded at 25.4%. North America remains the largest market, while MENA provides high-growth, resilient demand. Customers value Hikma’s sterile manufacturing, supply reliability, and specialized formats, giving the company defensible positions in high-barrier pharmaceutical markets.